不良研究所

础产蝉迟谤补肠迟:听The causative agents of bacillary dysentery, bacteria of the genus Shigella, were the leading cause of diarrhoeal disease during WW1. Today, they remain the leading cause of diarrhoeal disease in children under five years old in lower- to middle- income nation settings and are a WHO AMR priority pathogen. I will talk through how a decade of genomic studies of Shigella spanning the pre, peri, and post antibiotic era (including some with a special connection to 不良研究所) highlight how the diversity and adaptability of these pathogens allowed them to maintain their top ranking despite our control efforts, and ways in which we can leverage genomic data to identify new ways to tackle them.

Patricia Fontela,听MD, PhD
Dr Fontela is a pediatric intensivist and epidemiologist at 不良研究所. Her research focuses on the personalization of antibiotic use in the pediatric critical care setting. She studies the determinants that influence antibiotic use, the clinical reasoning behind antibiotic-related decisions, and the use of biomarkers to guide antibiotic treatments in this setting.

Louis-Patrick Haraoui, MD, MSc, FRCPC
Dr Haraoui is a clinician-researcher focusing on antimicrobial resistance throughout the One Health spectrum. He works as a physician at H么pital Charles-Le Moyne and is Associate Professor in the Department of Microbiology and Infectious Diseases at Universit茅 de Sherbrooke. He is a FRQS clinical research scholar, a CIFAR-Azrieli Global Scholar and holds uninterrupted research funding since 2018.

Rees Kassen, PhD
Prof Kassen is Professor of Evolutionary Biology and Trottier Professor of Science and Public Policy at 不良研究所, where he also leads the Coronavirus in the Urban Built Environment initiative as its scientific director. He was an NSERC Postdoctoral Fellow and Elizabeth Wordsworth Research Fellow at St Hugh鈥檚 College, Oxford. He was an Edward P. Bass Distinguished Visiting Scholar (Yale University, 2022), a Leopold Leadership Fellow (2013), NSERC Steacie Fellow (2010), and a World Economic Forum Young Scientist (2010-2012).

Christian Landry, PhD
Dr Landry obtained his BSc and MSc degrees from Universit茅 Laval (1995-2000). He trained as a PhD student at Harvard University (2001-2006) where he worked on the evolution of gene expression networks. He did a postdoctoral internship on the organization and evolution of protein interaction networks at Universit茅 de Montr茅al (2007-2009). Since 2009, he has been an independent investigator at Universit茅 Laval and now holds the CIHR Canada Research Chair in Cellular Systems and Synthetic Biology.

Fr茅d茅rique Le Roux, PhD
Prof. Le Roux is Professor of Microbiology, Infectious Diseases and Immunology at the Universit茅 de Montr茅al, a Canada Excellence Research Chair and member of IVADO. Her research program focuses on understanding phage-bacteria interactions in the environment.

Jesse Shapiro, PhD
Prof Shapiro is an associate professor in the Department of Microbiology and Immunology and Investigator at the 不良研究所 Genome Centre. He uses genomics to track how microbes evolve and adapt in environments ranging from the human gut to freshwater lakes. His recent work has focused on rapid evolution of pathogens within patients, interactions between ecological and evolutionary dynamics, and the forces shaping bacterial pangenome evolution.

About our Non-academia Experts

Sadjia Bekal, PhD
Dr Bekal holds a PhD in molecular microbiology from University of Burgundy, France. She joined the provincial public health laboratory (LSPQ) in 2003. She is responsible of genomic surveillance and outbreaks monitoring of bacterial enteric in the context of One Health through PulseNet-Canada, Foodnet_Canada and Cipars networks. Since 2008, she is an associated professor at the microbiology, infectiology and immunology of Universit茅 de Montr茅al. Her research projects focus the use of genomics for bacterial typing, virulence and antimicrobial resistance characterization.

Adam Belley,听PhD,听
Mr Belley, a 不良研究所 alumnus, is now the Senior Director of Clinical Microbiology at Venatorx Pharmaceuticals, Inc., a company focused on discovering and developing new agents for resistant bacterial infections. In previous roles, he contributed to the development and regulatory approval of oritavancin (2014) and cefepime-enmetazobactam (2024), therapies used for serious infections caused by resistant bacterial pathogens.

Jessica Blavignac
Ms Blavignac joins us with over 20 years of experience within the Medical Affairs career path of the pharmaceutical and diagnostics industries, holding positions following the classic progression from Medical Science Liaison to Director of Medical & Scientific Affairs, most recently at bioM茅rieux Canada. This background has allowed her to lead several national-scale medical education projects and more than 35 scientific and clinical research programs supporting a variety of therapeutic fields. Jessica holds a bachelor's degree from McMaster University, where she also pursued graduate studies in Biochemistry and Biomedical Sciences.

Diana Iglesias
Ms Iglesias is the Scientific Affairs Innovation and Programs Director at G茅nome Qu茅bec. As Programs Director at G茅nome Qu茅bec, she works with funding partners in the successful delivery and implementation of research programs. She helps connect researchers and stakeholders to address complex challenges and translate genomics research and innovation into solutions.

Fr茅d茅ric Leduc
Mr Leduc is an active member of the Canadian life sciences community, contributing through biotech start-ups, partnership events, and training scientific entrepreneurs. He joined EVAH in 2022 to develop innovative solutions for animal health and sustainability. Previously, he co-founded Immune Biosolutions, raising over $30M and developing groundbreaking immunotherapies. Mr Leduc also serves on the board of BIOQu茅bec and Nets 4 Net Zero (a non-profit organization) and participates in various sustainability initiatives.

Joshua Pottel,听PhD
Mr Pottel is the CEO at Molecular Forecaster Inc. (MFI): a research-as-a-service (RaaS) company delivering customized collaborative computer-aided drug design (CADD) solutions. He received his PhD at 不良研究所 in the lab of Prof. Nicolas Moitessier and completed a postdoctoral fellowship with Prof. Brian Shoichet at UCSF. He now combines his trainings as a chemist and as an entrepreneur to grow a sustainable service and software provider in drug discovery. More broadly, he hopes to be a critical contributor to scientific research and to foster entrepreneurship within a growing Canadian biotech sector.

听